Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

References

• Statistics Clearinghouse, NIH/NIDDK. Available from: diabetes.niddk.nih.gov. Accseesed on Apr 14, 2010.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAWAssociation of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): Prospective observational studyBMJ200032140541210938048
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34)Lancet19983528548659742977
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med20063552427244317145742
   PubMed Web of Science ®Google Scholar
• BrownJBNicholsGAPerryAThe burden of treatment failure in Type 2 diabetesDiabetes Care2004271535134015220224
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFrom the triumvirate to the ominous octet: A new paradigm for the treatment of Type 2 diabetes mellitusDiabetes20095877379519336687
   PubMed Web of Science ®Google Scholar
• BullockBPHellerRSHabenerJFTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptorEndocrinology1996137296829788770921
   PubMed Web of Science ®Google Scholar
• BrubakerPLDruckerDJStructure-function of the glucagon receptor family of G protein-coupled receptors: The glucagon, GIP, GLP-1, and GLP-2 receptorsReceptor Channels20028179188
   PubMedGoogle Scholar
• GedulinBLawlerRJodkaCYoungAAmylin inhibits pentagastrin-stimulated gastric acid secretion: Comparison with glucagon-like peptide-1 and exendin-4Diabetes199746 Abstr 188.
   Web of Science ®Google Scholar
• DeFronzoRAOkersonTViswanathanPEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over studyCurr Med Res Opin2008242943295218786299
   PubMed Web of Science ®Google Scholar
• SaydahSHFradkinJCowieCCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetesJAMA200429133534214734596
   PubMed Web of Science ®Google Scholar
• KoroCEBowlinSJBourgeoisNFedderDOGlycemic control from 1988 to 2000 among US adults diagnosed with Type 2 diabetes: A preliminary reportDiabetes Care200427172014693960
   PubMed Web of Science ®Google Scholar
• CheungBMYOngKLCherneySSDiabetes prevalence and therapeutic target achievement in the United States, 1999–2006Am J Med200912244345319375554
   PubMed Web of Science ®Google Scholar
• DeFronzoRAPathogenesis of Type 2 diabetes: Metabolic and molecular implications for identifying diabetes genesDiabetes Reviews19975177269
   Google Scholar
• DeFronzoRALilly lecture. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDMDiabetes1998376676873289989
   PubMedGoogle Scholar
• DeFronzoRAPathogenesis of Type 2 diabetes mellitusMed Clin N Am20048878783515308380
   PubMed Web of Science ®Google Scholar
• KahnSEClinical Review 135. The importance of beta-cell failure in the development and progression of Type 2 diabetesJ Clin Endocrinol Metab2001864047405811549624
   PubMed Web of Science ®Google Scholar
• BergmanRNFinegoodDTKahnSEThe evolution of beta-cell dysfunction and insulin resistance in Type 2 diabetesEur J Clin Invest200232354512028373
   PubMed Web of Science ®Google Scholar
• ReavenGMHollenbeckCJengC-YWuMSChenY-DIMeasurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDMDiabetes199837102011043292322
   PubMedGoogle Scholar
• McGarryJDBanting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of Type 2 diabetesDiabetes20025171811756317
   PubMed Web of Science ®Google Scholar
• BelfortRHarrisonSABrownKA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitisN Engl J Med20063552297230717135584
   PubMed Web of Science ®Google Scholar
• BodenGRole of fatty acids in the pathogenesis of insulin resistance and NIDDMDiabetes1997463108971073
   PubMed Web of Science ®Google Scholar
• BelfortRMandarinoLKashyapSDose-response effect of elevated plasma free fatty acid on insulin signalingDiabetes2005541640164815919784
   PubMed Web of Science ®Google Scholar
• RossettiLGiaccariADeFronzoRAGlucose toxicityDiabetes Care1990136106302192847
   PubMed Web of Science ®Google Scholar
• BaysHMandarinoLDeFronzoRARole of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of Type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approachJ Clin Endocrinol Metab20048946347814764748
   PubMed Web of Science ®Google Scholar
• RossettiLShulmanGIZawalichWDeFronzoRAEffect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized ratsJ Clin Invest198780103710443308956
   PubMed Web of Science ®Google Scholar
• KashyapSBelfortRGastaldelliAA sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop Type 2 diabetesDiabetes2003522461247414514628
   PubMed Web of Science ®Google Scholar
• GastaldelliAFerranniniEMiyazakiYMatsudaMDeFronzoRABeta-cell dysfunction and glucose intolerance: Results from the San Antonio Metabolism (SAM) studyDiabetologia200441313914666364
   PubMedGoogle Scholar
• Diabetes Prevention Research GroupReduction in the evidence of Type 2 diabetes with life-style intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• BuchananTAXiangAHPetersRKPreservation of pancreatic beta-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic womenDiabetes2002512796280312196473
   PubMed Web of Science ®Google Scholar
• BuchananTAXiangAHKjosSLDiabetes rates and B-cell function in the pioglitazone and prevention of diabetes (PIPOD) studyDiabetes200554Suppl 1A39
   Google Scholar
• DeFronzoRABanerjiMBrayGAActos NOW for the prevention of diabetes (ACT NOW) studyBMC Endocr Disord20099172519640291
   PubMed Web of Science ®Google Scholar
• WangQBrubakerPLGlucagon-like peptide-1 treatment delays the onset of diabetes in 8 week old db/db miceDiabetologia2002451263127312242459
   PubMed Web of Science ®Google Scholar
• GedulinBRNikoulinaSESmithPAExenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin resistant obese fa/fa Zucker rats independent of glycemia and body weightEndocrinology20051462069207615618356
   PubMed Web of Science ®Google Scholar
• AhrenBPaciniGFoleyJESchweizerAImproved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with Type 2 diabetes over 1 yearDiabetes Care2005281936194016043735
   PubMed Web of Science ®Google Scholar
• XuLManCDCharbonnelBEffect of sitagliptin, a dipeptidyl-peptidase 4 inhibitor, on beta-cell function in patients with Type 2 diabetes, a model-based approachDiabetes Obes Metab2008101212122018476982
   PubMed Web of Science ®Google Scholar
• MullerWAFaloonaGRAguilar-ParadaEUngerRHAbnormal alpha-cell function in diabetes: Response to carbohydrate and protein ingestionN Engl J Med19702831091154912452
   PubMed Web of Science ®Google Scholar
• UngerRHAguilar-ParadaEMullerWAEisentrautAMStudies of pancreatic alpha cell function in normal and diabetic subjectsJ Clin Invest1970498378484986215
   PubMed Web of Science ®Google Scholar
• Aguilar-ParadaEEisentrautAMUngerRHPancreatic glucagon secretion in normal and diabetic subjectsAm J Med Sci19692574154194893149
   PubMed Web of Science ®Google Scholar
• MatsudaMDeFronzoRAConsoliABresslerPDel PratoSDose-response curve relation plasma glucagon to hepatic glucose production and glucose disposal in Type 2 diabetes mellitusMetabolism2002511111111912200754
   PubMed Web of Science ®Google Scholar
• SchwartzJGGreenGMGuanDMcMahanCAPhillipsWTRapid gastric emptying of a solid pancake meal in Type II diabetic patientsDiabetes Care1996194684718732711
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMEffect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patientsJ Clin Endocrinol Metab2002872784279112050251
   PubMed Web of Science ®Google Scholar
• MiyazakiYDeFronzoRARosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in Type 2 diabetic patientsDiabetes Obes Metab2008101204121118476983
   PubMed Web of Science ®Google Scholar
• MatthewsDRCharbonnelBHHanefeldMBrunettiPSchernthanerGLong-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with Type 2 diabetes: A randomized, comparative studyDiabetes Metab Res Rev20052116717415386821
   PubMed Web of Science ®Google Scholar
• GastaldelliAFerranniniEMiyazakiYMatsudaMMariADeFronzoRAThiazolidinediones improve beta-cell function in Type 2 diabetic patientsAm J Physiol Endocrinol Metab2007292E871E88317106061
   PubMed Web of Science ®Google Scholar
• HanefeldMMarxNPfutznerAAnti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular-risk patients with elevated high sensitivity c-reactive protein: The PIOSTAT studyJ Am Coll Cardiol20074929029717239709
   PubMed Web of Science ®Google Scholar
• FernandezMTriplittCWajcbergEAddition of pioglitazone and ramipril to intensive insulin therapy in Type 2 diabetes patients improves vascular dysfunction by different mechanismsDiabetes Care20083112112717909084
   PubMed Web of Science ®Google Scholar
• WajcbergESriwijitkamolAMusiNDeFronzoRACersosimoERelationship between vascular reactivity and lipids in Mexican-Americans with Type 2 diabetes treated with pioglitazoneJ Clin Endocrinol Metab2007921256126217244785
   PubMed Web of Science ®Google Scholar
• GoldbergRBKendallDMDeegMAA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemiaDiabetes Care2005281547155415983299
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMBlochKDThe vascular biology of nitric oxide and its role in atherogenesisAnnu Rev Med1996473653758712788
   PubMed Web of Science ®Google Scholar
• de CaterinaRLibbyPPengHBNitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokinesJ Clin Invest19959660687542286
   PubMed Web of Science ®Google Scholar
• DefronzoRAInsulin resistance, lipotoxicity, Type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009Diabetologia2010531270128720361178
   PubMed Web of Science ®Google Scholar
• BajajMSuraamornkulSHardiesLJPratipanawatrTDeFronzoRAPlasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated Type 2 diabetic patientsInt J Obes200428783789
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMImproved glycemic control and enhanced insulin sensitivity in liver and muscle in Type 2 diabetic subjects treated with pioglitazoneDiabetes Care20012471071911315836
   PubMed Web of Science ®Google Scholar
• GastaldelliAMiyazakiYMahankaliAThe effect of pioglitazone on the liverDiabetes Care2006292275228117003306
   PubMed Web of Science ®Google Scholar
• GastaldelliAFerranniniEMiyazakiYMatsudaMMariADeFronzoRAThiazolidinediones improve beta-cell function in Type 2 diabetes patientsAm J Physiol Endocrinol Metab2007292E871E88317106061
   PubMed Web of Science ®Google Scholar
• ChiquetteERamirezGDeFronzoRA meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factorsArch Intern Med20041642097210415505122
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med20073562457247117517853
   PubMed Web of Science ®Google Scholar
• SinghSLokeUKFurbergCDLong-term risk of cardiovascular events with rosiglitazoneJAMA20072981189119517848653
   PubMed Web of Science ®Google Scholar
• MiyazakiYMatsudaMDefronzoRADose-response effect of pioglitazone on insulin sensitivity and insulin secretionin Type 2 diabetesDiabetes Care20022551752311874940
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 yearsCurr Med Res Opin20082427528618053320
   PubMed Web of Science ®Google Scholar
• The Dream (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trialLancet20063681096110516997664
   PubMed Web of Science ®Google Scholar
• BunckMCDiamontMCornerAOne-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated Type 2 diabetic patients: A randomized, controlled trialDiabetes Care20093276276819196887
   PubMed Web of Science ®Google Scholar
• DeFronzoRABanerjiMABrayGAfor the ACT NOW Study GroupDeterminants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW)Diabetologia20105343544520012012
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMAJenkinsonCPRichardsonDKTripathyDDeFronzoRAInsulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: Results from the Veterans Administration Genetic Epidemiology StudyDiabetes2006551430143516644701
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKPERISCOPE InvestigatorsComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: The PERISCOPE randomized controlled trialJAMA20082991561157318378631
   PubMed Web of Science ®Google Scholar
• MazzoneTMeyerPMFeinsteinSBEffect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: A randomized trialJAMA20062962572258117101640
   PubMed Web of Science ®Google Scholar
• CharbonnelBSchernthanerGBrunettiPLong-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with Type 2 diabetesDiabetologia2005481093110415889234
   PubMed Web of Science ®Google Scholar
• HanefeldMPfutznerAForstTLubbenGGlycemic control and treatment failure with pioglitazone versus glibenclamide in Type 2 diabetes mellitus: A 42-month, open-label, observational, primary care studyCurr Med Res Opin2006221211121516846554
   PubMed Web of Science ®Google Scholar
• TanMHBaksiAGLAL Study GroupComparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with Type 2 diabetesDiabetes Care20052854455015735185
   PubMed Web of Science ®Google Scholar
• RosenstockJGoldsteinBJVinikARESULT Study GroupEffect of early addition of rosiglitazone to sulphonylurea therapy in older Type 2 diabetes patients (60 years): The Rosiglitazone Early vs SULphonylurea Titration (RESULT) studyDiab Obes Metab200684957
   PubMed Web of Science ®Google Scholar
• HomePDJonesNPPocockSJRECORD Study GroupRosiglitazone RECORD study: Glucose control outcomes at 18 monthsDiabet Med20072462663417517066
   PubMed Web of Science ®Google Scholar
• MiyazakiYDeFronzoRARosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in Type 2 diabetic patientsDiabetes Obes Metab2008101204121118476983
   PubMed Web of Science ®Google Scholar
• RosmarakisESFalagasMEEffect of thiazolidinedione therapy on restenosis after coronary stent implantation: A meta-analysis of randomized controlled trialsAm Heart J200715414415017584567
   PubMed Web of Science ®Google Scholar
• LincoffAMWolskiKNichollsSJNissenSEPioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: A meta-analysis of randomized trialsJAMA2007 122981180118817848652
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJASecondary prevention of macrovascular events in patients with Type 2 diabetes in the proactive study (PROspective pioglitAzone Clincal Trial In macroVascular Events): A randomized controlled trialLancet20053661279128916214598
   PubMed Web of Science ®Google Scholar
• MiyazakiYGlassLTriplittCAbdominal fat distribution and peripheral and hepatic insulin resistance in Type 2 diabetes mellitusAm J Physiol Endocrinol Metab200246E1135E1481E114312424102
   PubMedGoogle Scholar
• PetersenKFDufourSShulmanGIDecreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of Type 2 diabetic parentsPLoS Medicine20052879884
   Web of Science ®Google Scholar
• NestoRWBellDBonowROThiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and the American Diabetes Association: Oct 7, 2003Circulation20031082941294814662691
   PubMed Web of Science ®Google Scholar
• KaulSBolgerAHerringtonDGiuglianoREckelRThiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology FoundationCirculation20101211868187720179252
   PubMed Web of Science ®Google Scholar
• MasoudiFAInzucchiSEWangYHavranekEPFoodyJMKrumholzHMThiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure; an observational studyCirculation200511158359015699279
   PubMed Web of Science ®Google Scholar
• PuschettJBPharmacological classification and renal actions of diureticsCardiology199484Suppl 24137954544
   PubMedGoogle Scholar
• KarallieddeJBuckinghamRStarkieMEffect of various diuretic treatments on rosiglitazone-induced fluid retentionJ Am Soc Nephrol2006173482349017093067
   PubMed Web of Science ®Google Scholar
• ValentineWJBottomleyJMPalmerAJPROactive Study GroupPROactive 06: Cost-effectiveness of pioglitazone in Type 2 diabetes in the UKDiabet Med200724982100217593245
   PubMed Web of Science ®Google Scholar
• NauckMStockmannFEbertRCreutzfeldtWReduced incretin effect in Type 2 (non-insulin-dependent) diabetesDiabetologia19862946523514343
   PubMed Web of Science ®Google Scholar
• VilsbollTHolstJJIncretins, insulin secretion and Type 2 diabetes mellitusDiabetologia20044735736614968296
   PubMed Web of Science ®Google Scholar
• MeierJJNauckMASchmidtWEGallwitzBGastric inhibitory polypeptide: The neglected incretin revisitedRegul Pept200210711312137960
   PubMed Web of Science ®Google Scholar
• Toft-NielsenMBDamholtMBMadsbadSDeterminants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetic patientsJ Clin Endocrinol Metab2001863717372311502801
   PubMed Web of Science ®Google Scholar
• DruckerDJGlucagon-like peptidesDiabetes1998471591699519708
   PubMed Web of Science ®Google Scholar
• JonesIROwensDRLuzioSWilliamsSHayesTMThe glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitusDiabetologia1989326686772676668
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMOrskovCPreserved incretin activity of glucagon-like peptide-1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with Type-2 diabetes mellitusJ Clin Invest1993913013078423228
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetesLancet20063681696170517098089
   PubMed Web of Science ®Google Scholar
• DeaconCFIncretin-based treatment of Type 2 diabetes: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsDiabetes Obes Metab20079Suppl 1233117877544
   PubMed Web of Science ®Google Scholar
• FerranniniEBjorkmanOReichardGAPiloAOlsonMThe disposal of an oral glucose load in healthy subjects. A quantitative studyDiabetes1985345805883891471
   PubMed Web of Science ®Google Scholar
• AhrenBGut peptides and Type 2 diabetes mellitus treatmentCurr Diab Rep2003336537212975025
   PubMedGoogle Scholar
• AhrenBInsulinotropic action of truncated glucagon-like peptide-1 in miceActa Physiol Scand19951532052067778462
   PubMedGoogle Scholar
• DruckerDJPhilippeJMojsovSChickWLHabenerJFGlucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell lineProc Natl Acad Sci U S A19878434343033647
   PubMed Web of Science ®Google Scholar
• KashimaYMikiTShibasakiTCritical role of cAMP-GEFII – Rim2 complex in incretin-potentiated insulin secretionJ Biol Chem2001276460464605311598134
   PubMed Web of Science ®Google Scholar
• FehmannHCGokeRGokeBGlucagon-like peptide-1(7–37)/(7–36) amide is a new incretinMol Cell Endocrinol199285C39C441382025
   PubMed Web of Science ®Google Scholar
• WangYEganJMRaygadaMNadivORothJMontrose-RafizadehCGlucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cellsEndocrinology1995136491049177588224
   PubMed Web of Science ®Google Scholar
• FehmannHCHabenerJFInsulinotropic hormone glucagon-like peptide-I(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cellsEndocrinology19921301591661309325
   PubMed Web of Science ®Google Scholar
• FehmannHCHabenerJFGalanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-I(7–37) in mouse insulinoma beta TC-1 cellsEndocrinology1992130289028961374016
   PubMed Web of Science ®Google Scholar
• DruckerDJGlucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosisMol Endocrinol20031716117112554744
   PubMed Web of Science ®Google Scholar
• MullerWAFaloonaGRAguilar-ParadaEUngerRHAbnormal alpha-cell function in diabetes: Response to carbohydrate and protein ingestionN Engl J Med19702831091154912452
   PubMed Web of Science ®Google Scholar
• UngerRHAguilar-ParadaEMullerWAEisentrautAMStudies of pancreatic alpha cell function in normal and diabetic subjectsJ Clin Invest1970498378484986215
   PubMed Web of Science ®Google Scholar
• Aguilar-ParadaEEisentrautAMUngerRHPancreatic glucagon secretion in normal and diabetic subjectsAm J Med Sci19692574154194893149
   PubMed Web of Science ®Google Scholar
• LarssonHBerglundGAhrenBGlucose modulation of insulin and glucagon secretion is altered in impaired glucose toleranceJ Clin Endocrinol Metab199580177817827775622
   PubMed Web of Science ®Google Scholar
• AhrenBLarssonHImpaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrationsDiabetologia2001441998200311719830
   PubMed Web of Science ®Google Scholar
• LarssonHAhrenBGlucose intolerance is predicted by low insulin secretion and high glucagon secretion: Outcome of a prospective study in postmenopausal Caucasian womenDiabetologia20004319420210753041
   PubMed Web of Science ®Google Scholar
• UngerRHGlucagon physiology and pathophysiologyN Engl J Med19712854434494997492
   PubMed Web of Science ®Google Scholar
• HellerRSKiefferTJHabenerJFInsulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreasDiabetes1997467857919133545
   PubMed Web of Science ®Google Scholar
• KoltermanOGBuseJBFinemanMSSynthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetesJ Clin Endocrinol Metab2003883082308912843147
   PubMed Web of Science ®Google Scholar
• HorowitzMDentJFraserRSunWHebbardGRole and integration of mechanisms controlling gastric emptyingDig Dis Sci199439Suppl 127S13S7995220
   PubMedGoogle Scholar
• PhillipsWTSchwartzJGMcMahanCARapid gastric emptying of an oral glucose solution in Type 2 diabetic patientsJ Nucl Med199233149615001634941
   PubMed Web of Science ®Google Scholar
• HorowitzMFraserRDisordered gastric motor function in diabetes mellitusDiabetologia1994375435517926337
   PubMed Web of Science ®Google Scholar
• SchwartzJGGreenGMGuanDMcMahanCAPhillipsWTRapid gastric emptying of a solid pancake meal in Type II diabetic patientsDiabetes Care1996194684718732711
   PubMed Web of Science ®Google Scholar
• HorowitzMEdelbroekMAWishartJMStraathofJWRelationship between oral glucose tolerance and gastric emptying in normal healthy subjectsDiabetologia1993368578628405758
   PubMed Web of Science ®Google Scholar
• PhillipsWTSchwartzJGMcMahanCARapid gastric emptying of an oral glucose solution in Type 2 diabetic patientsJ Nucl Med19923314965001634941
   PubMed Web of Science ®Google Scholar
• KoltermanOGKimDDShenLPharmacokinetics, pharmacodynamics, and safety of exenatide in patients with Type 2 diabetes mellitusAm J Health Syst Pharm20056217318115700891
   PubMed Web of Science ®Google Scholar
• ImeryuzNYegenBCBozkurtACoskunTVillanueva-PenacarrilloMLUlusoyNBGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanismsAm J Physiol1997273G920G9279357836
   PubMed Web of Science ®Google Scholar
• OrskovCPoulsenSSMollerMHolstJJGlucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide IDiabetes1996458328358635662
   PubMed Web of Science ®Google Scholar
• Tang-ChristensenMLarsenPJGokeRCentral administration of GLP-1-(7–36) amide inhibits food and water intake in ratsAm J Physiol1996271R848R8568897973
   PubMed Web of Science ®Google Scholar
• TurtonMDO’SheaDGunnIA role for glucagon-like peptide-1 in the central regulation of feedingNature199637969728538742
   PubMed Web of Science ®Google Scholar
• AhrenBGlucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetesBioessays1998206426519780839
   PubMed Web of Science ®Google Scholar
• VerdichCFlintAGutzwillerJPA meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humansJ Clin Endocrinol Metab2001864382438911549680
   PubMed Web of Science ®Google Scholar
• DeaconCFNauckMAToft-NielsenMPridalLWillmsBHolstJJBoth subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjectsDiabetes199544112611317657039
   PubMed Web of Science ®Google Scholar
• FengJZhangZWallaceMBDiscovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IVJ Med Chem2007502297230017441705
   PubMed Web of Science ®Google Scholar
• AsakawaTMoritohYKataokaOSuzukiNTakeuchiKOdakaHA novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failureLife Sci20098512212619427871
   PubMed Web of Science ®Google Scholar
• MoritohYTakeuchiKAsakawaTKataokaOdakaHChronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob miceEur J Pharmacol200858832533218499100
   PubMed Web of Science ®Google Scholar
• ChristopherRCovingtonPDavenportMPharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in health male subjectsClin Ther20083051352718405789
   PubMed Web of Science ®Google Scholar
• Onglyza^® [package insert]Princeton, NJBristol-Myers Squibb2009
   Google Scholar
• Januvia^® [package insert]Whitehouse Station, NJMerck and Company, Inc.2010
   Google Scholar
• CovingtonPChristopherRDavenportMPharmacokinetic, pharmacodynamic, and tolerability prof iles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind placebo-controlled multiple-dose study in adult patients with Type 2 diabetesClin Ther20083049951218405788
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFleckPRWilsonCAMekkiQEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes and inadequate glycemic controlDiabetes Care2008312315231718809631
   PubMed Web of Science ®Google Scholar
• PratleyREKipnesMSFleckPRWilsonCMekkiQEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes inadequately controlled by glyburide monotherapyDiabetes Obes Metab20091116717619125778
   PubMed Web of Science ®Google Scholar
• NauckMAEllisGCFleckPRWilsonCAMekkiQEfficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: A multicenter, randomized, double-blind, placebo-controlled studyInt J Clin Pract200963465519125992
   PubMed Web of Science ®Google Scholar
• RosenstockJRendellMSGrossJLFleckPRWilsonCAMekkiQAloglitpin added to insulin therapy in patients with Type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemiaDiabetes Obes Metab2009111145115219758359
   PubMed Web of Science ®Google Scholar
• KarimACovingtonPChristopherRPharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: A two-phase, crossover study in health subjectsInt J Clin Pharmacol Ther201048465820040339
   PubMed Web of Science ®Google Scholar
• KarimALaurentAMunsakaMWannEFleckPMekkiQCoadministration of pioglitazone or glyburide and alogliptin: Pharmacokinetic drug interaction assessment in healthy participantsJ Clin Pharmacol2009491210121919622714
   PubMed Web of Science ®Google Scholar
• PratleyRReuschJFleckPWilsonCMekkiQEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with Type 2 diabetes: A randomized, double-blind, placebo-controlled studyCurr Med Res Opin2009252361237119650752
   PubMed Web of Science ®Google Scholar
• DeFronzoRABurantCFFleckPWilsonCMekkiQPratleyREEffect of alogliptin combined with pioglitazone in glycemic control in metformin-treated patients with Type 2 diabetesDiabetes200958Suppl 1A519 Abstr 2023.
   Google Scholar
• DefronzoRABurantCFFleckPWilsonCMekkiQPratleyREEffect of alogliptin combined with pioglitazone on glycemic control in metformin-treated patients with Type 2 diabetesDiabetes200958Suppl 1A519A520 Abstr 2024.
   Google Scholar
• RosenstockJInzucchiSSeufertJFleckPWilsonCMekkiQEfficacy and safety of alogliptin combined with pioglitazone in patients with Type 2 diabetes inadequately controlled with diet and exerciseDiabetes200958Suppl 1A523 Abstr 2036.
   PubMedGoogle Scholar
• InzucchiSERosenstockJSeufertJFleckPWilsonCMekkiQEffect of combination therapy with alogliptin and pioglitazone in drug-naïve patients with Type 2 diabetes on b-cell function and insulin resistanceDiabetes200958Suppl 1A520 Abstr 2026.
   PubMedGoogle Scholar